Serotonin and Noradrenaline Reuptake Inhibitors (SNRI) updated on 07-01-2025

Nervous system anomalies

R analysis
id Study   Lib. in paper Exposition period    Study type  Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S18317
R77148
Chan (Controls unexposed, sick), 2024 Nervous system malformations 1st trimester retrospective cohort (claims database) unexposed, sick Adjustment: No Monotherapy: SSRI only Unexposed sick: old history of illness/treatment (> 12 months before pregnancy) or not specified 0.92 [0.06;15.07] C 0/66   36/4,413 36 66
ref
S18315
R77124
Chan - SNRI (Controls exposed to TCA), 2024 Nervous system malformations 1st trimester retrospective cohort (claims database) exposed to other treatment, sick excluded Adjustment: No Monotherapy: SNRI only 0.59 [0.03;11.64] C
excluded (control group)
0/77   3/322 3 77
ref
S18316
R77136
Chan - SNRI (Controls unexposed, general pop), 2024 Nervous system malformations 1st trimester retrospective cohort (claims database) unexposed (general population or NOS) excluded Adjustment: No Monotherapy: SNRI only 1.58 [0.10;25.57] C
excluded (control group)
0/77   1,899/462,377 1,899 77
ref
S15171
R62279
Benevent - SNRI, 2023 Nervous system anomalies 1st trimester retrospective cohort (claims database) unexposed (general population or NOS) Adjustment: No Monotherapy: SNRI only 1.79 [0.25;12.83] C 1/314   261/146,855 262 314
ref
S11684
R42948
Ankarfeldt a - Duloxetine (Controls unexposed, NOS), 2021 Nervous system malformations 1st trimester population based cohort retrospective unexposed (general population or NOS) excluded Adjustment: Yes Monotherapy: no or not specified 1.00 [0.28;3.54]
excluded (control group)
-/1,438   12/5,751 - 1,438
ref
S11685
R42964
Ankarfeldt a - Duloxetine (Controls unexposed, sick), 2021 Nervous system malformations 1st trimester population based cohort retrospective unexposed, sick Adjustment: Yes Monotherapy: no or not specified Unexposed sick: intermediate history of illness/treatment (3-12 months before pregnancy) 1.50 [0.25;8.98] -/1,434   -/1,435 - 1,434
ref
S11745
R43129
Huybrechts - Duloxetine (Controls unexposed, NOS), 2020 Central Nervous System malformations 1st trimester retrospective cohort (claims database) unexposed (general population or NOS) excluded Adjustment: Yes Monotherapy: no or not specified 0.81 [0.30;2.16]
excluded (control group)
-/2,532   -/- - 2,532
ref
S11746
R43143
Huybrechts - Duloxetine (Controls unexposed, sick), 2020 Central Nervous System malformations 1st trimester retrospective cohort (claims database) unexposed, sick Adjustment: Yes Monotherapy: no or not specified Unexposed sick: intermediate history of illness/treatment (3-12 months before pregnancy) 0.67 [0.18;2.42] -/2,532   -/2,456 - 2,532
ref
S11696
R43024
Bérard b - SNRI=Venlafaxine (Controls unexposed, sick), 2017 Nervous system malformations 1st trimester retrospective cohort (claims database) unexposed, sick Adjustment: Yes Monotherapy: SNRI only Unexposed sick: intermediate history of illness/treatment (3-12 months before pregnancy) 1.19 [0.55;2.58] -/738   -/14,847 - 738
ref
Total 5 studies 1.11 [0.62;1.99] 298 5,084
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Chan (Controls unexposed, sick), 2024Chan, 2024 1 0.92[0.06; 15.07]36664%ROB confusion: criticalROB selection: moderateROB classification: moderateROB missing: lowROB mesure: moderateROB reporting: moderate Benevent - SNRI, 2023Benevent - SNRI, 2023 1.79[0.25; 12.83]2623149%ROB confusion: criticalROB selection: lowROB classification: criticalROB missing: unclearROB mesure: moderateROB reporting: moderate Ankarfeldt a - Duloxetine (Controls unexposed, sick), 2021Ankarfeldt a - Duloxetine, 2021 2 1.50[0.25; 8.98]-1,43411%ROB confusion: seriousROB selection: moderateROB classification: criticalROB missing: lowROB mesure: moderateROB reporting: low Huybrechts - Duloxetine (Controls unexposed, sick), 2020Huybrechts - Duloxetine, 2020 3 0.67[0.18; 2.42]-2,53220%ROB confusion: moderateROB selection: moderateROB classification: criticalROB missing: unclearROB mesure: moderateROB reporting: low Bérard b - SNRI=Venlafaxine (Controls unexposed, sick), 2017Bérard b - SNRI=Venlafaxine, 2017 4 1.19[0.55; 2.58]-73856%ROB confusion: seriousROB selection: moderateROB classification: criticalROB missing: lowROB mesure: moderateROB reporting: moderate Total (5 studies) I2 = 0% 1.11[0.62; 1.99]2985,0840.25.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Controls unexposed, sick; 2: Controls unexposed, sick; 3: Controls unexposed, sick; 4: Controls unexposed, sick;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 1.11[0.62; 1.99]2985,0840%NAChan (Controls unexposed, sick), 2024 Benevent - SNRI, 2023 Ankarfeldt a - Duloxetine (Controls unexposed, sick), 2021 Huybrechts - Duloxetine (Controls unexposed, sick), 2020 Bérard b - SNRI=Venlafaxine (Controls unexposed, sick), 2017 5 case control studiescase control studies 0 Type of controls unexposed (disease free or unspecified)unexposed (disease free or unspecified) 1.79[0.25; 12.83]262314 -NABenevent - SNRI, 2023 1 unexposed, sickunexposed, sick 1.06[0.58; 1.96]364,7700%NAChan (Controls unexposed, sick), 2024 Ankarfeldt a - Duloxetine (Controls unexposed, sick), 2021 Huybrechts - Duloxetine (Controls unexposed, sick), 2020 Bérard b - SNRI=Venlafaxine (Controls unexposed, sick), 2017 4 Tags Adjustment   - No  - No 1.44[0.29; 7.19]2983800%NAChan (Controls unexposed, sick), 2024 Benevent - SNRI, 2023 2   - Yes  - Yes 1.07[0.58; 2.00]-4,7040%NAAnkarfeldt a - Duloxetine (Controls unexposed, sick), 2021 Huybrechts - Duloxetine (Controls unexposed, sick), 2020 Bérard b - SNRI=Venlafaxine (Controls unexposed, sick), 2017 3 Monotherapy   - no or not specified  - no or not specified 0.88[0.31; 2.53]-3,9660%NAAnkarfeldt a - Duloxetine (Controls unexposed, sick), 2021 Huybrechts - Duloxetine (Controls unexposed, sick), 2020 2   - SNRI only  - SNRI only 1.26[0.61; 2.58]2621,0520%NABenevent - SNRI, 2023 Bérard b - SNRI=Venlafaxine (Controls unexposed, sick), 2017 2   - SSRI only  - SSRI only 0.92[0.06; 15.07]3666 -NAChan (Controls unexposed, sick), 2024 1 Unexposed sick   - intermediate history of illness/tre ...  - intermediate history of illness/treatment (3-12 months before pregnancy) 1.07[0.58; 2.00]-4,7040%NAAnkarfeldt a - Duloxetine (Controls unexposed, sick), 2021 Huybrechts - Duloxetine (Controls unexposed, sick), 2020 Bérard b - SNRI=Venlafaxine (Controls unexposed, sick), 2017 3   - old history of illness/treatment (> ...  - old history of illness/treatment (> 12 months before pregnancy) or not specified 0.92[0.06; 15.07]3666 -NAChan (Controls unexposed, sick), 2024 1 All studiesAll studies 1.11[0.62; 1.99]2985,0840%NAChan (Controls unexposed, sick), 2024 Benevent - SNRI, 2023 Ankarfeldt a - Duloxetine (Controls unexposed, sick), 2021 Huybrechts - Duloxetine (Controls unexposed, sick), 2020 Bérard b - SNRI=Venlafaxine (Controls unexposed, sick), 2017 50.25.01.0

Publication bias and p-hacking diagnosis

funnel plot
0.0-3.43.51.7150.000Chan (Controls unexposed, sick), 2024Benevent - SNRI, 2023Ankarfeldt a - Duloxetine (Controls unexposed, sick), 2021Huybrechts - Duloxetine (Controls unexposed, sick), 2020Bérard b - SNRI=Venlafaxine (Controls unexposed, sick), 2017

Asymetry test p-value = 0.9140 (by Egger's regression)

slope=0.0660 (0.3962); intercept=0.0702 (0.5979); t=0.1173; p=0.9140

p values plot
0.01.00.01.0

Sub-groups analysis using all included studies

excluded 11745, 11684, 18315, 18316

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 1.00[0.49; 2.01]2,1644,3610%NAChan - SNRI (Controls unexposed, general pop), 2024 Benevent - SNRI, 2023 Ankarfeldt a - Duloxetine (Controls unexposed, NOS), 2021 Huybrechts - Duloxetine (Controls unexposed, NOS), 2020 4 unexposed, sick controlsunexposed, sick controls 1.06[0.58; 1.96]364,7700%NAChan (Controls unexposed, sick), 2024 Ankarfeldt a - Duloxetine (Controls unexposed, sick), 2021 Huybrechts - Duloxetine (Controls unexposed, sick), 2020 Bérard b - SNRI=Venlafaxine (Controls unexposed, sick), 2017 4 exposed to other treatment, sick controlsexposed to other treatment, sick controls 0.59[0.03; 11.64]377 -NAChan - SNRI (Controls exposed to TCA), 2024 10.510.01.0

Umbrella review (other published meta-analyses)

Published MAControlPeriodTE95% CIn exposedkI2 Huang - SNRIs (Congenital malformations of th ...Huang - SNRIs (Congenital malformations of the nervous system) 2.28[1.50; 3.45]0%-U,GPunexposed (general population or NOS)Anyduring pregnancy (anytime or not specified)studies TTT-9 Lou - SNRIs (Nervous system malformations)Lou - SNRIs (Nervous system malformations) 1.06[0.47; 2.40]0%-Eexposed to other treatment, sickT11st trimesterstudies TTT2 Lou - SNRIs (Nervous system malformations)Lou - SNRIs (Nervous system malformations) 1.07[0.58; 2.00]0%-U,Sunexposed, sickT11st trimesterstudies TTT3 Lou - SNRIs (Nervous system malformations)Lou - SNRIs (Nervous system malformations) 0.88[0.40; 1.91]0%-U,GPunexposed (general population or NOS)T11st trimesterstudies TTT2 metaPregmetaPreg 1.11[0.62; 1.99]0%5,084----Chan (Controls unexposed, sick), 2024 Benevent - SNRI, 2023 Ankarfeldt a - Duloxetine (Controls unexposed, sick), 2021 Huybrechts - Duloxetine (Controls unexposed, sick), 2020 Bérard b - SNRI=Venlafaxine (Controls unexposed, sick), 2017 50.510.01.0